ProCE Banner Activity

ExpressPoints
Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma—Experts Address the Paradox of Choice

Slideset Download
Gain key clinical insights fast, with this short summary slideset from CCO on key considerations for optimal treatment selection for patients with relapsed/refractory myeloma.

Released: June 25, 2021

Expiration: June 24, 2022

No longer available for credit.

Share

Faculty

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nina Shah

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Peter Michael Voorhees

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

GlaxoSmithKline

Karyopharm

Oncopeptides

Sanofi Genzyme

Program Director Disclosure

Program Director

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty Disclosure

Primary Author

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Peter Michael Voorhees, MD

Assistant Professor of Medicine
Department of Hematology/Oncology
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina